Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Christopher KennardEmeritus Professor of Clinical Neurology, Professor Christopher Kennard joins the Medical Sciences Division as its new interim Head of Division today, replacing Professor Alastair Buchan, who will be taking a new role as the University’s Head of Brexit Strategy. Professor Kennard knows the Division well, having served, until his retirement late last year, as the Head of the Nuffield Department of Clinical Neuroscience, one of the 16 departments within the Division. Prior to his arrival in Oxford, Prof Kennard was the Deputy Principal for the Faculty of Medicine at Imperial College, London.

Professor Christopher Kennard commented:  “It is a great honour to have been invited by the VC to take on the role of interim Head of the Medical Sciences Division, following Alastair Buchan’s move to become the Head of Brexit Strategy for the University. During his nine year tenure he successfully led the Division to its premier international position and made major contributions in many areas. I very much look forward to being able to contribute to the Division’s continuing success and to work with such an exceptionally talented group of teachers and researchers.”

Professor Louise Richardson, Vice-Chancellor, said: “I am deeply grateful to Professor Christopher Kennard for agreeing to assume the role of Head of Division on an interim basis until a new Head of Division is appointed. The Division sought Council’s approval for the process of selecting a new Head of Division, and we expect to have a new head in place before Professor Alastair Buchan’s term would ordinarily have concluded.”

Similar stories

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.